Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27593170 | 0.91 | CA1 (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2061401 | 0.91 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7155961 | 0.91 | ALDH1A1 (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| Benzene SCHEMBL27441781 | 0.89 | CA1 (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3589537 | 0.88 | TAAR1 (0.47) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17372880 | 0.87 | TAAR1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2996214 | 0.87 | TAAR1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4852971 | 0.87 | TAAR1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL3128402 | 0.87 | TAAR1 (0.47) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL29006859 | 0.86 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10297757-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-1694334-B1 | TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2332543-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | ABBOTT GMBH & CO. KG. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137186-A1 | Tetrahydrobenzazepines and their use | DRD3, ADRB3, AVPR1B | KDM4E 3117/4885USP2 4699/4885ALDH1A1 1176/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | KDM4E 729/4885USP2 3900/4885ALDH1A1 77/4885 |
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | KDM4E 1558/4885USP2 3820/4885ALDH1A1 4324/4885 |
| US-20170137426-A1 | HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, MERTK | KDM4E 3883/4885USP2 2270/4885ALDH1A1 3773/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | KDM4E 1772/4885USP2 4011/4885ALDH1A1 4102/4885 |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | DRD3, DRD2, ADRB3 | KDM4E 3533/4885USP2 4703/4885ALDH1A1 809/4885 |
| US-10297757-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element and electronic device | TERT, PIEZO1, ETV6 | KDM4E 1248/4885USP2 3818/4885ALDH1A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.